Commercial strategy built for healthcare innovation and responsible adoption.
From clearance to clinical adoption. US Health Strategy Group helps emerging health technology companies enter the U.S. market with the physician alignment, workflow strategy, governance structure, and commercial discipline required for responsible growth.
The firm
Founder-led. Scope-defined.
US Health Strategy Group is founder-led and scope-defined. Every engagement is structured around a specific decision: a market, a buyer, a clinical pathway, or a compliance structure. The output is a plan the organization can execute, not a deck to present.
Services
Strategy that connects market opportunity to execution.
Focused advisory for organizations entering, validating, rebuilding, or expanding in complex U.S. healthcare markets.
Market Entry & Commercial Strategy
Choose the market, clarify the buyer, and build a plan the organization can execute.
Explore →Adoption, Evidence & Innovation
Build the path from interest to responsible adoption without losing clinical integrity.
Explore →Commercial Execution & Strategic Advisory
Build the operating tools, field frameworks, and advisory infrastructure that move strategy into the market.
Explore →KOL Strategy & Advisory Development
Define, map, engage, activate, and sustain compliant physician and expert networks.
Explore →The problem
Healthcare innovation fails for reasons that go beyond the product.
Clinical evidence, workflow fit, stakeholder alignment, reimbursement access, and commercial execution must be developed together. When they are not, adoption stalls regardless of the product's merit.
See how the work is structuredClinical leaders need to understand where the technology fits before it enters their workflow.
Companies need credible KOL infrastructure before broad market claims can be made or believed.
Research and commercial strategy need to connect, without crossing compliance boundaries.
Payer, policy, and provider realities must be mapped to the product's actual cleared indication.
Focus areas
Added depth where adoption is clinically and operationally complex.
These areas inform the work without limiting the broader commercialization platform. Two shown here, with two more, including Veteran Health & VA and Digital Health & Healthcare AI, on the full page.
Explore all 4 focus areasNeuromodulation & VNS
PNS, SCS, VNS, taVNS, and advanced interventional therapies: where clinical evidence, procedure economics, and payer coverage determine commercial outcomes.
MSK & Value-Based Care
PT, rehab, and musculoskeletal care delivery, with direct experience in value-based model design, bundled payments, and provider network strategy.
Market context
The commercialization landscape in numbers.
Benchmark data and market context that frame the work US Health Strategy Group is designed to address.
Market reality
The Cost of an Unstructured Market Entry
The difference between structured and unstructured commercial entry is not marginal. It is measured in years and in capital.
- 12 to 36 months to sustainable clinical adoption
- $500K to $2M+ in misallocated commercial spend (Source: Bain & Company medtech commercialization study)
- KOL relationships built ad hoc without compliance infrastructure
- Evidence gaps discovered after market entry
- No replicable playbook for geographic or indication expansion
- Defined adoption pathway before market spend
- KOL tier architecture mapped to indication and geography
- Research and evidence plan aligned to commercial timeline
- Compliant physician engagement from day one
- Replicable commercial infrastructure built to scale
Medtech companies that align clinical and commercial strategy in year one reach sustainable market adoption 2 to 3 times faster than those that treat adoption as a post-launch problem.
Insights
Analysis and reference that inform the work.
Original analysis on medtech commercialization, plus the clinical literature, market research, and regulatory guidance behind it.
The Structured Commercial Strategy Framework for Cleared Medtech
FDA clearance is a regulatory event, not a commercial one. Five structural components that connect regulatory reality to clinical workflow and adoption.
Why 95% of Healthcare AI Deployments Fail Before Scale
Digital health and healthcare AI products are failing at the adoption stage, not the clinical validation stage. Here is what drives it.
Building a Compliant KOL Network: What Medtech Companies Get Wrong
Sunshine Act reporting and OIG fair market value guidance have made KOL engagement a discipline with material legal exposure.
Start with the decision in front of you.
Share the product, market, stage, and the decision that needs to be made. US Health Strategy Group will recommend the most useful starting scope.